Exome Asset Management LLC Has $1.71 Million Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

Exome Asset Management LLC increased its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT) by 24.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 352,056 shares of the company’s stock after acquiring an additional 69,656 shares during the quarter. Exome Asset Management LLC’s holdings in Rezolute were worth $1,707,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RZLT. Virtu Financial LLC increased its holdings in shares of Rezolute by 58.0% in the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after acquiring an additional 9,551 shares in the last quarter. Jeppson Wealth Management LLC acquired a new position in shares of Rezolute in the 2nd quarter valued at approximately $45,000. MML Investors Services LLC bought a new stake in Rezolute during the 3rd quarter worth approximately $57,000. State Street Corp raised its holdings in Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after buying an additional 13,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Rezolute in the third quarter valued at approximately $65,000. 82.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans acquired 9,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $4.60 per share, with a total value of $41,400.00. Following the completion of the transaction, the chief financial officer now directly owns 140,900 shares in the company, valued at approximately $648,140. This represents a 6.82 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.39% of the company’s stock.

Rezolute Stock Performance

Shares of NASDAQ RZLT opened at $4.59 on Friday. The stock has a 50 day moving average price of $5.16 and a 200 day moving average price of $4.77. The stock has a market capitalization of $265.96 million, a PE ratio of -3.61 and a beta of 1.01. Rezolute, Inc. has a 52 week low of $0.81 and a 52 week high of $6.19.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). As a group, research analysts forecast that Rezolute, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RZLT. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research report on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. BTIG Research boosted their price target on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Finally, Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $24.13.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.